Allergan may have a reputation as a serial buyer, but it’s not looking for any big deals, CEO Brent Saunders insisted on Monday. And that assurance could quiet the rumors that the company is eyeing a Biogen buy.
As Saunders pointed out on Allergan’s Q2 conference call, the company has been focused on so-called “stepping stone” deals, and that’s what it’s looking at now.
Allergan’s recently canceled Pfizer megamerger notwithstanding, “It’s not like it’s a new strategy, despite our image … in the market,” he said.
That was a “once in a corporate lifetime situation,” Saunders insisted. These days, “we’re not looking for big M&A,” he said, though “while the odds of something compelling become clear are exceptionally low,” they’re “not zero,” he pointed out.
Meanwhile, in the wake of Allergan’s just-closed deal to send its generics unit off to Teva–and another recent pact that’ll transfer its generics distribution business to the Israeli drugmaker, too–Teva’s base business “looks good,” Evercore ISI analyst Umer Raffat wrote in a note to clients. Key products Botox and Restasis netted $719.7 million and $390.6 million in quarterly sales, respectively, with their year-over-year growth offsetting a $38.2 million decline for now-off-patent Alzheimer’s med Namenda.
Overall, the heavy hitters led revenue to $3.68 billion–and while that figure fell short of the $4.08 billion consensus mark, that consensus hadn’t been updated for the generics distribution sale, Raffat pointed out. Allergan put up a net loss of $1.44 per share, which has widened since the company posted a loss of 80 cents in the year-ago period.
Allergan’s full-year guidance suffered on the distribution deal, too; while the business primarily supported the company’s former generics unit, branded revenues took a $100 million hit, leading the Dublin drugmaker to revise its sales guidance downward. It now expects between $14.75 billion and $15 billion for the year, as opposed to the $15 billion it previously forecast.
By Carly Helfan
Source: Fierce Pharma
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
